By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Report: Thymosin ?4 Prevents Heart Rupture & Improves Cardiac Function After Heart Attack In Mice 7/15/2014 7:32:01 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX)’s Strategic Partner G-Treebnt Preparing For Phase 3 Dry Eye Trials In Asia With RGN-259 7/7/2014 10:16:00 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Chinese FDA Accepts Phase 2 IND For RGN-259 For Dry Eye 6/23/2014 11:45:39 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Issues Letter To Shareholders 5/22/2014 8:04:12 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives $1.35 Million Pursuant To Product License And Stock Purchase Agreement 3/31/2014 8:36:57 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) And Digital Aria Sign Product License And Stock Purchase Agreements 3/7/2014 8:40:12 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Israeli Patent For Treatment Of Dry Eye Syndrome 2/24/2014 9:11:42 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance From U.S. Patent Office For Treatment And Prevention Of Neuro And Muscular Degenerative Diseases 1/16/2014 8:49:08 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Orphan Drug Designation For Tß4 In The Treatment Of Neurotrophic Keratopathy 1/3/2014 8:58:59 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance From Canadian Patent Office For Reversal Of Skin Aging 12/20/2013 10:20:12 AM
12345678910...
//-->